Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ruvise

- PMLiVE

Novartis buys cancer specialist Endocyte for $2.1bn

Acquisition includes 'universal' CAR-T platform

- PMLiVE

CHMP delays decision on Kiadis’ GVHD immunotherapy

Medicines regulator issues out Day 180 List of Outstanding Issues

- PMLiVE

Novartis files for approval of MS drug in EU, US

Siponimod could achieve blockbuster status if approved, says analysts

- PMLiVE

Stakeholder dialogue in Europe’s adaptive pathways pilot

Is enhanced dialogue with wide stakeholder groups crucial to being able to respond to an unmet medical need?

- PMLiVE

New chair for Europe’s key medicines committee

Appointment comes amid Brexit-induced disruption and new era in medicines

Novartis day

Novartis cuts manufacturing jobs in Switzerland and UK

Cuts include closure of Grimsby site by 2020

- PMLiVE

NHS wins legal fight with pharma over off-label Avastin

Industry criticises judgement - fearful of 'undermining regulation' as well as big earning products

- PMLiVE

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Proactive adjuvant treatment could extend melanoma patient lives

- PMLiVE

Health secretary’s ‘rip off’ remarks anger UK pharma

Row with Vertex has tainted government-industry relations

- PMLiVE

Novartis sells off part of Sandoz portfolio

Swiss pharma giant will retain biosimilars

Sanofi reception

Sanofi gets EU OK for Ablynx flagship drug Cablivi

EMA clears the drug to treat adults with aTTP

- PMLiVE

Novartis wins key adjuvant Taf/Mek approval in Europe

Ex-GSK duo on course for first blockbuster year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links